• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 2:04:34 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHVN alert in real time by email
    SC 13G 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _ )*

                

    Biohaven Pharmaceutical Holding Co. Ltd.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G11196105


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G11196105

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital World Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 4,649,448
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 4,649,448
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,649,448 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.8%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Biohaven Pharmaceutical Holding Co. Ltd.
    (b) Address of Issuer's Principal Executive Offices
    215 Church Street, 234 Church Street, New Haven, CT 6510
    Item 2.
    (a) Name of Person Filing
    Capital World Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G11196105
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    4,649,448 **
    (b) Percent of Class:
    7.8%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 4,649,448
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 4,649,448
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl and Capital International K.K. (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 4,649,448 shares or 7.8% of the 59,939,166 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital World Investors
    By: /s/ Michael J. Triessl
    Date: February 16, 2021
    Name: Michael J. Triessl
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $BHVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BHVN

    DatePrice TargetRatingAnalyst
    2/11/2025$65.00Buy
    Deutsche Bank
    9/16/2024$57.00Buy
    Jefferies
    9/4/2024$55.00Outperform
    Bernstein
    7/24/2024$58.00Overweight
    Morgan Stanley
    2/16/2024$62.00Outperform
    RBC Capital Mkts
    2/6/2024$59.00Buy
    UBS
    12/22/2023$50.00Buy
    H.C. Wainwright
    12/8/2023$58.00Outperform
    Robert W. Baird
    More analyst ratings

    $BHVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Deutsche Bank initiated coverage on Biohaven with a new price target

      Deutsche Bank initiated coverage of Biohaven with a rating of Buy and set a new price target of $65.00

      2/11/25 7:01:45 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Biohaven with a new price target

      Jefferies initiated coverage of Biohaven with a rating of Buy and set a new price target of $57.00

      9/16/24 7:22:04 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bernstein initiated coverage on Biohaven with a new price target

      Bernstein initiated coverage of Biohaven with a rating of Outperform and set a new price target of $55.00

      9/4/24 7:31:23 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Childs John W bought $996,238 worth of shares (32,700 units at $30.47) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 7:01:52 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Director Childs John W bought $2,999,970 worth of shares (73,170 units at $41.00) (SEC Form 4)

      4/A - Biohaven Ltd. (0001935979) (Issuer)

      3/5/25 6:59:47 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Childs John W bought $1,042,393 worth of shares (29,000 units at $35.94) (SEC Form 4)

      4 - Biohaven Ltd. (0001935979) (Issuer)

      12/31/24 7:00:14 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Financials

    Live finance-specific insights

    See more
    • Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

      Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

      9/23/24 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

      Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

      9/20/24 7:09:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

      Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

      3/22/23 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

      Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

      5/12/23 4:30:00 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biohaven Announces Investment up to $600 Million by Oberland Capital

      Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales$250 million to be funded at closing$150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expensesNEW HAVEN, Conn., April 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseas

      4/28/25 7:30:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

      SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer

      4/5/25 9:00:00 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/14/24 3:06:46 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/12/24 1:20:24 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

      SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

      11/4/24 11:16:33 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Antonijevic Irina

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:16:02 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Heffernan Michael Thomas

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:15:04 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bailey Gregory

      4 - Biohaven Ltd. (0001935979) (Issuer)

      5/7/25 5:14:32 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BHVN
    SEC Filings

    See more
    • Biohaven Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Biohaven Ltd. (0001935979) (Filer)

      5/7/25 5:18:11 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Biohaven Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Biohaven Ltd. (0001935979) (Filer)

      4/28/25 7:59:17 AM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Biohaven Ltd.

      DEFA14A - Biohaven Ltd. (0001935979) (Filer)

      3/18/25 4:48:49 PM ET
      $BHVN
      Biotechnology: Pharmaceutical Preparations
      Health Care